Aptevo Therapeutics (APVO) announced executive leadership transitions to support the Company’s continued execution, drive achievement of long-term strategic objectives, and next phase of growth. Effective April 1, Marvin White, who has served as President and CEO since 2016, has chosen to retire from this position and assume the role of Executive Chair, where he will focus on cultivating strategic opportunities to help shape long-term success. Jeff Lamothe, currently COO, will assume the role of President and CEO and will join Aptevo’s Board of Directors. John Niederhuber will transition from Chairman of the Board to Lead Independent Director.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APVO:
- Aptevo Therapeutics files to sell 7.075M shares of common stock for holders
- Aptevo Therapeutics Secures $60 Million Equity Financing Facility
- Aptevo Therapeutics secures $60M equity line of credit
- Aptevo Therapeutics trading halted, news pending
- Aptevo Therapeutics Implements 1-for-18 Reverse Stock Split